NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I'm wondering if perhaps we're reading SI-87 in error. It's the "specials" wording that makes me wonder if SI-87 patient specific labeling is meant to enable treatments such as DCVax-L to be made and given to patients with other cancer indications, like breast or lung, etc.

Meanwhile, the MAA process continues at what ever stage it's at, but when approved, SI-87 will not apply to DCVax-L for GBM or recurrent GBM, as the MA will cover it.

Thoughts?